- Trials with a EudraCT protocol (717)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
717 result(s) found for: Visual system.
Displaying page 1 of 36.
EudraCT Number: 2016-000102-11 | Sponsor Protocol Number: NL55949 | Start Date*: 2016-11-23 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. | |||||||||||||
Medical condition: Parkinson's disease patients with refractory visual hallucinations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002112-27 | Sponsor Protocol Number: MD1003CT2013-01MS-ON | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:MEDDAY SAS | ||||||||||||||||||
Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study | ||||||||||||||||||
Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004787-30 | Sponsor Protocol Number: MOVING | Start Date*: 2012-10-26 |
Sponsor Name:Charite Universitaetsmedizin Berlin | ||
Full Title: Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® | ||
Medical condition: Multiple sclerosis or clinically isolated syndrom | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-000282-37 | Sponsor Protocol Number: AIFA-2016-02365063 | Start Date*: 2020-02-26 | |||||||||||
Sponsor Name:DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA | |||||||||||||
Full Title: Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase | |||||||||||||
Medical condition: Spinocerebellar ataxia type 7 (SCA7) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002531-15 | Sponsor Protocol Number: 09/0959 | Start Date*: 2016-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UCL Comprehensive Clinical Trials Unit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005017-12 | Sponsor Protocol Number: EyeADHD-01 | Start Date*: 2014-03-31 | |||||||||||
Sponsor Name:Parnassia Bavo Groep - PsyQ | |||||||||||||
Full Title: Looking into the eye of ADHD. Investigating the relationship between ADHD, the delayed circadian rhythm and the functioning of the eye. | |||||||||||||
Medical condition: Adults with ADHD and suboptimal eye functioning. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002204-27 | Sponsor Protocol Number: GS030_CLIN_001 | Start Date*: 2017-12-22 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa | ||
Medical condition: Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003451-30 | Sponsor Protocol Number: Euro-SCD-FBB2 | Start Date*: 2017-02-14 | |||||||||||
Sponsor Name:Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | |||||||||||||
Full Title: Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study. | |||||||||||||
Medical condition: Subjects with subjective cognitive decline. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005113-39 | Sponsor Protocol Number: SSP-2 | Start Date*: 2013-04-08 |
Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien | ||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis | ||
Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015586-31 | Sponsor Protocol Number: 190342-031D | Start Date*: 2010-01-29 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug ... | |||||||||||||
Medical condition: Rhegmatogenous Macula-off Retinal Detachment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-005039-94 | Sponsor Protocol Number: IC2019-05 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Institut Curie | |||||||||||||
Full Title: RETINO 2018 : Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome. | |||||||||||||
Medical condition: Retinoblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003271-35 | Sponsor Protocol Number: KU-AIM-01-2018 | Start Date*: 2019-01-07 | |||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||
Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS | |||||||||||||
Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005798-75 | Sponsor Protocol Number: NVI-114 | Start Date*: 2008-02-21 |
Sponsor Name:Neo Vista Inc. | ||
Full Title: Estudio prospectivo, aleatorizado y controlado de Epi-Rad90™, sistema oftálmico para el tratamiento de la neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asoc... | ||
Medical condition: neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asociada a la edad | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004955-64 | Sponsor Protocol Number: E2090-S082-403 | Start Date*: 2017-04-21 |
Sponsor Name:Eisai Korea Inc. | ||
Full Title: A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2008-001487-37 | Sponsor Protocol Number: 190342-032D | Start Date*: 2008-11-05 |
Sponsor Name:Allergan Limited | ||
Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br... | ||
Medical condition: Geographic Atrophy from Age-related Macular Degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-002696-10 | Sponsor Protocol Number: CCPK850X2202 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c... | |||||||||||||
Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001405-90 | Sponsor Protocol Number: GS-LHON/CLIN/01 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:GENSIGHT-BIOLOGICS | |||||||||||||
Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations... | |||||||||||||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004980-39 | Sponsor Protocol Number: Amiloride02 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis | |||||||||||||
Medical condition: Optic Neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003677-66 | Sponsor Protocol Number: RESTORE | Start Date*: 2022-02-14 | |||||||||||
Sponsor Name:Amsterdam University Medical Center | |||||||||||||
Full Title: Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis | |||||||||||||
Medical condition: Multiple sclerosis (MS) Internuclear ophthalmoparesis (INO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003226-71 | Sponsor Protocol Number: MR42410 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ... | |||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
